Literature DB >> 6413200

Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans.

J M Warter, C Marescaux, C Brandt, L Rumbach, G Micheletti, G Chabrier, M Imler, D Kurtz.   

Abstract

Treatment with sodium valproate (VPA) in association with phenobarbital (PB) is accompanied by a greater systemic hyperammonemia than treatment by VPA alone. The anatomical origins of this difference were studied by injecting a dose of 1,500 mg VPA i.v. into six unmedicated patients and six epileptics chronically treated with PB and measuring the ammonium (NH4+) concentration difference between arterial blood and renal, hepatic, internal jugular, and femoral venous blood. In unmedicated patients, arterial [NH4+] rose moderately, secondary to an increased amount of NH4+ released into the general circulation by the kidney; the hepatic metabolism of NH4+ remained normal. In epileptics treated with PB, arterial [NH4+] rose massively, partly as a result of the increased NH4+ release by the kidney and partly because of disturbance of the hepatic metabolism of NH4+. These results provide a clearer understanding of the potentiation of the secondary effects of VPA by PB.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413200     DOI: 10.1111/j.1528-1157.1983.tb03428.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.

Authors:  R N Ratnaike; G J Schapel; G Purdie; R H Rischbieth; S Hoffmann
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Exercises in clinical reasoning: a confusing interaction.

Authors:  Urvi A Shah; Mark C Henderson; Paul Abourjaily; David Thaler; Joseph Rencic
Journal:  J Gen Intern Med       Date:  2015-01-27       Impact factor: 5.128

Review 3.  Roles of renal ammonia metabolism other than in acid-base homeostasis.

Authors:  I David Weiner
Journal:  Pediatr Nephrol       Date:  2016-05-12       Impact factor: 3.714

4.  Valproic acid induction of coma in rats: synergism with NH4+ and pentobarbital.

Authors:  L Zieve; C Lyftogt
Journal:  Metab Brain Dis       Date:  1989-06       Impact factor: 3.584

5.  Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.

Authors:  M Paganini; G Zaccara; F Moroni; R Campostrini; L Bendoni; G Arnetoli; R Zappoli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  State of stupor from valproic acid during chronic treatment: case report.

Authors:  S Gentile; C Buffa; C Ravetti; I Sacerdote
Journal:  Ital J Neurol Sci       Date:  1991-04

7.  Valproate-induced hyperammonaemia in two epileptic identical twins.

Authors:  R Campostrini; G Zaccara; L Rossi; M Paganini; A Dorigotti; R Zappoli
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 8.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 9.  Interorgan ammonia trafficking in liver disease.

Authors:  Steven W M Olde Damink; Rajiv Jalan; Cornelius H C Dejong
Journal:  Metab Brain Dis       Date:  2008-12-09       Impact factor: 3.584

10.  Hyperammonemic Encephalopathy due to Valproic Acid and Topiramate Interaction.

Authors:  Jennifer D Twilla; Andrew S Pierce
Journal:  Case Rep Psychiatry       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.